Therefore, combination treatment incorporating dulanermin with other synergistic agents may provide an effective therapeutic potential in the treatment of breast cancer, where TRAIL’s pro-apoptotic effects can be restored, and the agents can be used to selectively induce cancer cell death. The gene discussed is TNFSF10; the disease is breast cancer.